

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claims 1-5 (Canceled).

6. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition comprising phanquinone and a compound, or a mixture of compounds, selected from the group comprising antioxidants, acetylcholine enhancers, trace metals, prosthetic groups and clioquinol provided, when clioquinol is selected, that at least one further compound is selected from the said group.

Claims 7-12 (Canceled).

13. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~any of the claims~~ claim 6 to 10, comprising phanquinone, clioquinol and vitamin B<sub>12</sub>.

Claims 14-41 (Canceled).

42. (Original) A pharmaceutical composition comprising (a) an amount of phanquinone effective to treat or prevent Alzheimer's disease, and (b) a compound or a mixture of compounds selected from the group comprising antioxidants, acetylcholine enhancers, trace metals, prosthetic groups and clioquinol, provided, when clioquinol is selected, at least one further compound is selected from said group.

43. (Currently Amended) ~~The pharmaceutical composition,~~ composition according to claim 42, wherein the total amount of the compounds in (b) is sufficient for increasing the effect of the treatment of Alzheimer's disease or for inhibiting any detrimental side effect.

44. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 42, wherein the amount of (b) the compound(s) is 5 µg to 250 mg.

45. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 42, wherein the antioxidant is selected from the group comprising vitamin C, vitamin E, Q10, or combinations thereof.

46. (Original) The pharmaceutical composition according to claim 42, wherein the acetylcholine enhancer is tacrine.

47. (Original) The pharmaceutical composition according to claim 42, wherein the acetylcholine enhancer is donepezil.

48. (Original) The pharmaceutical composition according to claim 42, wherein the prosthetic group is vitamin B<sub>12</sub>.

49. (Original) A pharmaceutical composition, comprising (a) an amount of phanquinone effective to treat or prevent Alzheimer's disease, and (b) a mixture of clioquinol and vitamin B<sub>12</sub>.

50. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to any of the claims 42 or 49, which further comprises a pharmaceutical acceptable carrier.

51. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to any of the claims ~~42, 49 or 50~~ 42 or 49, wherein the amount of phanquinone is 5 to 250 mg.

52. (Currently Amended) The pharmaceutical composition according to any of the claims ~~42, 49 or 50~~ 42 or 49, wherein the amount of phanquinone is 10 mg to 50 mg.

53. (Currently Amended) The pharmaceutical composition according to ~~any of the claims 42, 49 or 50~~ claim 49, comprising an amount of clioquinol effective to improve the treatment or prevention of Alzheimer's disease.

54. (Currently Amended) The pharmaceutical composition according to ~~any of the claims 42, 49 or 50~~ claim 49, comprising an amount of vitamin B<sub>12</sub> effective to inhibit a detrimental side effect of clioquinol administration.

55. (Currently Amended) ~~Pharmaceutical~~ The pharmaceutical composition according to ~~any of the claims 42, 49 or 50~~ claim 49, wherein the amount of clioquinol is 5 mg to 250 mg.

56. (Currently Amended) The pharmaceutical composition according to ~~any of the claims 42, 49 or 50~~ claim 49, wherein the amount of clioquinol is 10 mg to 50 mg.

57. (Currently Amended) The pharmaceutical composition according to claim 49 ~~or~~ 50, wherein the amount of vitamin B<sub>12</sub> is 5 µg to 2 mg.

58. (Currently Amended) The pharmaceutical composition according to claim 49 ~~or~~ 50, wherein the amount of vitamin B<sub>12</sub> is 0.5 mg to 1 mg.

59. (Currently Amended) The pharmaceutical composition according to claim 42, ~~49~~ ~~or~~ ~~50~~ 42 or 49, wherein the composition is formulated for parenteral administration.

60. (Currently Amended) The pharmaceutical composition according to claim 42, ~~49~~ ~~or~~ ~~50~~ 42 or 49, wherein the composition is formulated for intradermal administration.

61. (Currently Amended) The pharmaceutical composition according to claim 42, ~~49~~ ~~or~~ ~~50~~ 42 or 49, wherein the composition is formulated for oral administration.

62. (Currently Amended) The pharmaceutical composition according to claim 42, ~~49~~ ~~or~~ ~~50~~ 42 or 49, wherein the composition is formulated as a tablet.

63. (Currently Amended) The pharmaceutical composition according to claim 42, ~~49~~ ~~or~~ ~~50~~ 49, wherein the clioquinol and vitamin B<sub>12</sub> are formulated in separate pharmaceutical entities, phanquinone being formulated together with clioquinol, vitamin B<sub>12</sub>, or separate.

64. (Original) A kit comprising in one or more containers an amount of phanquinone and clioquinol effective to treat or prevent Alzheimer's disease, and an amount of vitamin B<sub>12</sub> effective to inhibit a detrimental side effect of clioquinol administration.